PKD2相关常染色体显性多囊肾病:患病率、临床表现、突变谱与预后
基于法国西部22个肾内科中心的Genkyst队列,纳入293例PKD2突变患者(203个家系),结合ExAC数据库估算遗传患病率。结果显示PKD2相关ADPKD通常表现轻微,60岁时ESRD累积概率为9.8%,高血压概率为75.2%;肾功能加速恶化时应排查合并肾病。
要点
- PKD2患者60岁时ESRD累积概率9.8%,高血压概率75.2%。
- 男性肾功能低于女性,但肾脏生存无性别差异。
- 18例60岁前进展至ESRD者中44%合并可能解释早期进展的疾病或肾病。
核心结论
- PKD2相关ADPKD患者通常表现为轻微疾病。
- 若肾功能加速恶化,应排查合并肾病。
研究设计与样本
- 病例系列研究,时间范围为2010年1月至2016年3月。
- Genkyst研究参与者为来自法国西部22个肾内科中心的18岁以上个体,ADPKD诊断依据Pei标准或无家族史时至少10个双侧肾囊肿。
- 利用ExAC数据库公开的全外显子测序数据估算疾病的遗传患病率。
- 对PKD1和PKD2基因进行分子分析,结局包括肾脏生存及年龄和性别校正的估算肾小球滤过率。
主要发现
- Genkyst队列包括293例PKD2突变患者(203个家系)。
- 有肾内科随访的PKD2患者在布列塔尼的患病率为0.63(95%CI,0.54-0.72)/10,000,而PKD2遗传患病率在欧洲人群中计算为1.64(95%CI,1.10-3.51)/10,000居民。
- 诊断中位年龄为42岁;胁腹痛报告于38.9%的患者,肉眼血尿31.1%,囊肿感染15.3%。
- 60岁时ESRD累积概率为9.8%(95%CI,5.2%-14.4%),高血压概率为75.2%(95%CI,68.5%-81.9%)。
- 男性肾脏功能低于女性,但肾脏生存无性别影响;非截短突变(n=36)与更高的年龄校正eGFR相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 年轻患者和表现为较轻型PKD2相关疾病的患者可能未被诊断或未转诊至肾内科中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PKD2-related autosomal dominant polycystic kidney disease (ADPKD) is widely acknowledged to be of milder severity than PKD1-related disease, but population-based studies depicting the exact burden of the disease are lacking. We aimed to revisit PKD2 prevalence, clinical presentation, mutation spectrum, and prognosis through the Genkyst cohort. STUDY DESIGN: Case series, January 2010 to March 2016. SETTINGS & PARTICIPANTS: Genkyst study participants are individuals older than 18 years from 22 nephrology centers from western France with a diagnosis of ADPKD based on Pei criteria or at least 10 bilateral kidney cysts in the absence of a familial history. Publicly available whole-exome sequencing data from the ExAC database were used to provide an estimate of the genetic prevalence of the disease. OUTCOMES: Molecular analysis of PKD1 and PKD2 genes. Renal survival, age- and sex-adjusted estimated glomerular filtration rate. RESULTS: The Genkyst cohort included 293 patients with PKD2 mutations (203 pedigrees). PKD2 patients with a nephrology follow-up corresponded to 0.63 (95% CI, 0.54-0.72)/10,000 in Brittany, while PKD2 genetic prevalence was calculated at 1.64 (95% CI, 1.10-3.51)/10,000 inhabitants in the European population. Median age at diagnosis was 42 years. Flank pain was reported in 38.9%; macroscopic hematuria, in 31.1%; and cyst infections, in 15.3% of patients. At age 60 years, the cumulative probability of end-stage renal disease (ESRD) was 9.8% (95% CI, 5.2%-14.4%), whereas the probability of hypertension was 75.2% (95% CI, 68.5%-81.9%). Although there was no sex influence on renal survival, men had lower kidney function than women. Nontruncating mutations (n=36) were associated with higher age-adjusted estimated glomerular filtration rates. Among the 18 patients with more severe outcomes (ESRD before age 60), 44% had associated conditions or nephropathies likely to account for the early progression to ESRD. LIMITATIONS: Younger patients and patients presenting with milder forms of PKD2-related disease may not be diagnosed or referred to nephrology centers. CONCLUSIONS: Patients with PKD2-related ADPKD typically present with mild disease. In case of accelerated degradation of kidney function, a concomitant nephropathy should be ruled out.
引用
- Cornec-Le Gall E, Audrézet MP, Renaudineau E, et al. PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis. Am J Kidney Dis. 2017. PMID: 28356211. doi:10.1053/j.ajkd.2017.01.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。